← Leaderboards
Dung L Thai
Remd Biotherapeutics, Inc.
$826,833
Attributed
$1,653,666
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $748.1K · FY2016–18$1M$750K$500K$250K$0
'16
'17
'18
Funding mix
By agency
NIH$1,653,666 · 1
By mechanism
R42$1,653,666 · 1
Top collaborators
- Samuel Klein3 shared
Most similar at Remd Biotherapeutics, Inc.
Same institution · by research overlap
- Dung "zung" Thai$1,490,470
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseAdverse EventAnimal ModelAffinityAlkaline PhosphataseAutoimmune ProcessBenignBilirubinAnimalsBloodBlood GlucoseBlood Glucose RegulationBlood LipidBusinessesCardiovascular SystemChronicClinical EfficacyClinical ResearchC-PeptideDiabetes MellitusDiabeticDiabetic PatientDiabetic RatDouble-Blind Method
Grant awards (3)
Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes$680,901
R42 · FY2018 · DK
Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes$748,101
R42 · FY2017 · DK
Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes$224,664
R42 · FY2016 · DK